Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques - Wikidata - awgldk - TriplyDB

Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques

Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques

http://www.wikidata.org/entity/Q28775900

about

In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial Antiretroviral therapy for prevention of HIV infection: new clues from an animal model.Tenofovir-associated bone density loss.Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques.Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure Aging, human immunodeficiency virus, and bone health.Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Evaluation of degradation kinetics and physicochemical stability of tenofovir Safety and tolerability of antiretrovirals during pregnancy.A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAART Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009 Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.HIV and bone metabolism Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.Tenofovir-induced kidney injury.Tenofovir and bone health.Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.Differences in Serum Levels of Magnesium, Phosphate, and Albumin for HAART-Experienced and HAART-Naïve Female Patients Attending Parirenyatwa Opportunistic Infections Clinic in Harare, Zimbabwe Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study Chronic hepatitis B virus infection and pregnancy.Pharmacogenetics of tenofovir treatment.M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures.

P2860

Q24674939-097FAB87-F5DD-4979-947F-D952DAF25835 Q26744617-103DF7CF-893B-4FFC-9324-460D568D9D4A Q28472146-A9F0706C-2719-4EAF-807A-0D82846365AA Q28483723-1B031ED5-BFCC-43CA-8E36-DE3A95468E1E Q33318541-9AE1AAF3-6DF0-4527-9706-F95949551A67 Q33635034-868DCBE1-DD1A-4565-BEB5-B04AD51FBD27 Q33644248-F192FE69-D52D-4A8E-ACAB-023DFF4511EB Q33653655-64ACEEA7-824F-4ECB-8365-56C61E8B0D7D Q33759543-A6470514-D086-4C6F-8771-EA77978CB873 Q33770127-4066A9AD-870B-467B-A1B1-9EC8B4F0CA9D Q33843148-FFE084DF-2339-4339-B95E-6E6C3837BA2C Q33880241-852B8F3C-BD3B-4FAE-99EE-B7C18C3A6192 Q34160511-B4206442-9C9A-4A54-905D-E096AD1BCDBE Q34371989-6E732CE5-34AA-4661-AA61-53E5447CF6C9 Q34409132-255FFAC4-6088-4D37-8E56-8310EA0A1A8F Q34686870-879124C7-3BF3-45BF-AF26-DB143AA34566 Q34785122-F7A7352C-CA48-4F81-86B3-67A8841671C8 Q34981966-54C295B0-603F-43DD-ADBC-11050A52D16A Q34990151-94643692-7266-4EAC-9054-9F3B757540C0 Q35024276-66632E0B-49C1-49CF-94CC-A83079DC5DED Q35088292-0BCA26FE-57C0-4197-8D77-B508EA7655AF Q35598502-E65A8D24-5D43-40AC-B9FE-61AB6AEF304C Q35659264-50233587-4A3F-4FD0-9C19-92133D36AE03 Q35752812-15065DD4-80B5-463E-8FFB-9794219AF314 Q35869263-B18737FC-51B2-4DFB-BD0D-EDBFBDE0574E Q35984276-BCA0E404-087B-478D-B3AB-B306B823E4EB Q36164175-178EF3AF-30A8-43C5-98BB-153F4FD557F6 Q36333957-4F227E50-5E30-4A41-8697-13F0D2D16EAA Q36448494-6B894A83-1D9C-4D5D-BF4C-7F0E189E9EB3 Q36671233-AF876F96-F850-4D17-8B9D-BF9B854FB362 Q36723349-034AF6A0-5546-4C23-B546-C371A67567E8 Q36762441-A886C5BB-D272-483A-A19F-CEA58A88B363 Q36833961-CA15EFEA-6E3C-413C-8BE8-406A865A0DF2 Q36870864-EA5F5122-A82C-4906-BC74-1DB17AE17997 Q37111444-E830C35C-82BB-48D0-8F76-9E88841BB625 Q37182852-DD618D76-B398-4F22-8484-16ED4850BDC0 Q37596221-BFCC8448-639B-4F6C-9D18-A603419A82A9 Q37613468-157A61AF-C269-45B3-8C5E-7C4E639E17F1 Q37618231-67ABC842-AF77-462D-B371-CA68F5BB6E08 Q37618276-0DC19B67-449B-40B5-A402-71397683B8E3

P2860

Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques

http://www.wikidata.org/entity/Q28775900

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Biological effects of short-te ...... orn and infant rhesus macaques

@ast

Biological effects of short-te ...... orn and infant rhesus macaques

@en

type

label

Biological effects of short-te ...... orn and infant rhesus macaques

@ast

Biological effects of short-te ...... orn and infant rhesus macaques

@en

prefLabel

Biological effects of short-te ...... orn and infant rhesus macaques

@ast

Biological effects of short-te ...... orn and infant rhesus macaques

@en

P1433

Q28775900-30A7EEE3-96C9-4F08-9C3B-718132BA5B03

P1476

Q28775900-4F99F455-9FEB-4993-8B2D-B75D976441A7

P2093

Q28775900-098689E3-A0B3-429C-A591-F3FE59CD92B9

Q28775900-1D95CFAD-B55D-4593-9327-412AFBFB1C62

Q28775900-458C36DF-88EA-4813-84FC-D3BFCC9366B2

Q28775900-473AAEBC-D40A-433C-8491-3B52ABB91A7A

Q28775900-49055F0B-7545-4A0D-A24F-E38D24FA1596

Q28775900-4D9645C6-5E01-4AD5-B370-2A7694A56A3D

Q28775900-4EA6B2CD-D87F-4A5A-94FC-3961C64DEE19

Q28775900-52C42B11-F2F2-4C2B-8A3C-D8519A2BDF59

Q28775900-5362F317-2904-47F3-8D39-E74E03C5497D

Q28775900-58AB6EF6-8286-490F-936B-A0A20BB8EC30

P2860

Q28775900-01C6C53F-A0BA-46CF-872E-D7937B478551

Q28775900-044D775D-7351-46C7-93E0-86390E31843D

Q28775900-0F184715-686A-4AF3-A9AA-10AE3A73CED3

Q28775900-14EC9056-44A4-41DA-AFEE-658DB33CDB3F

Q28775900-1B47AF17-5FFE-4484-B440-7C63A5E1A5A2

Q28775900-223BD973-122C-461D-8EAF-D84F705980D3

Q28775900-320B5550-DF9B-4283-94E6-2E41C4FF798D

Q28775900-34AA1BE5-10DE-4CC4-8075-3D04B4848C3A

Q28775900-37D15720-A39E-4BE1-873A-798DB734CB6E

Q28775900-3D2A849B-C998-4BA0-ACC9-D1CAA8A70379

P304

Q28775900-5EA02E2F-F7E2-482B-8258-9663E7629DFF

P31

Q28775900-E7957810-A093-4901-8F1D-632F21F01E8D

P3181

Q28775900-9A2000CD-F0AB-43F4-AA2C-4B0DEB3E8213

P356

Q28775900-5BC4E462-4A10-4660-B02D-CC9902D883D6

P407

Q28775900-6E0A6A42-8108-4DFF-9451-CFFC415AA122

P433

Q28775900-C8ECDCE8-C653-4488-A949-5208B6B6C2C9

P478

Q28775900-2A73899A-ADAC-457B-8C24-39C7EF5FE371

P50

Q28775900-11A689F5-AED5-4992-A4E1-CAF9C421BB99

P577

Q28775900-82FD4A06-6313-48F2-9901-CCC896599337

P698

Q28775900-9EF929B9-755D-4419-AD06-C93A0ECDF112

P921

Q28775900-A3DF6F61-9CA8-40AE-BD5B-B56EA4F99CDA

P932

Q28775900-96B6C009-604F-4292-8DE5-867DC535DC15

P3181

P356

AAC.48.5.1469-1487.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Biological effects of short-te ...... orn and infant rhesus macaques

@en

P2093

Abigail Spinner

http://www.w3.org/2001/XMLSchema#string

Celia Valverde

http://www.w3.org/2001/XMLSchema#string

Christopher Jerome

http://www.w3.org/2001/XMLSchema#string

David R Bennett

http://www.w3.org/2001/XMLSchema#string

Dennis J Meyer

http://www.w3.org/2001/XMLSchema#string

Don R Canfield

http://www.w3.org/2001/XMLSchema#string

John Desjardins

http://www.w3.org/2001/XMLSchema#string

Koen K A Van Rompay

http://www.w3.org/2001/XMLSchema#string

Laurie L Brignolo

http://www.w3.org/2001/XMLSchema#string

Linda L Hirst

http://www.w3.org/2001/XMLSchema#string

P2860

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.

Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.

Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.

Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection

Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial.

9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA

P304

1469-1487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1420883

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.48.5.1469-1487.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Alesha B Castillo

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15105094

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

P932

400569

http://www.w3.org/2001/XMLSchema#string